pubmed-article:8446254 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:8446254 | lifeskim:mentions | umls-concept:C0003232 | lld:lifeskim |
pubmed-article:8446254 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:8446254 | lifeskim:mentions | umls-concept:C0019004 | lld:lifeskim |
pubmed-article:8446254 | lifeskim:mentions | umls-concept:C0041044 | lld:lifeskim |
pubmed-article:8446254 | lifeskim:mentions | umls-concept:C0011209 | lld:lifeskim |
pubmed-article:8446254 | lifeskim:mentions | umls-concept:C0085416 | lld:lifeskim |
pubmed-article:8446254 | lifeskim:mentions | umls-concept:C0055007 | lld:lifeskim |
pubmed-article:8446254 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
pubmed-article:8446254 | lifeskim:mentions | umls-concept:C1442080 | lld:lifeskim |
pubmed-article:8446254 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
pubmed-article:8446254 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:8446254 | pubmed:dateCreated | 1993-4-8 | lld:pubmed |
pubmed-article:8446254 | pubmed:abstractText | Twenty-three stabilized chronic uremic patients with no active or recent infection were treated for 10 days with either cefodizime (5 x 2 g intravenously, n = 10) or cotrimoxazole (960 mg orally b.i.d., n = 8) in order to evaluate the effects on the depressed polymorphonuclear metabolic response to phagocytic challenge; a separate group of 5 patients received placebo. Ex vivo evaluation in whole blood of energy delivery to the phagocytosis-associated respiratory burst activity in response to latex and zymosan challenge was determined by measuring hexose-monophosphate shunt NAD(P)H-oxidase-related glycolytic activity. Cefodizime induced a statistically significant increase in the baseline-depressed glycolytic response for both latex and zymosan challenge, in contrast to cotrimoxazole and placebo. Depressed phagocytosis-related metabolic function in hemodialyzed patients was stimulated by cefodizime in recommended therapeutic doses but not by cotrimoxazole, the effect persisting for at least 2 weeks after the end of treatment. | lld:pubmed |
pubmed-article:8446254 | pubmed:language | eng | lld:pubmed |
pubmed-article:8446254 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8446254 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:8446254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8446254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8446254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8446254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8446254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8446254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8446254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8446254 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:8446254 | pubmed:issn | 0028-2766 | lld:pubmed |
pubmed-article:8446254 | pubmed:author | pubmed-author:VanholderRR | lld:pubmed |
pubmed-article:8446254 | pubmed:author | pubmed-author:DagrosaE EEE | lld:pubmed |
pubmed-article:8446254 | pubmed:author | pubmed-author:RingoirS MSM | lld:pubmed |
pubmed-article:8446254 | pubmed:author | pubmed-author:Van... | lld:pubmed |
pubmed-article:8446254 | pubmed:author | pubmed-author:WaterloosM... | lld:pubmed |
pubmed-article:8446254 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:8446254 | pubmed:volume | 63 | lld:pubmed |
pubmed-article:8446254 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:8446254 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:8446254 | pubmed:pagination | 65-72 | lld:pubmed |
pubmed-article:8446254 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:meshHeading | pubmed-meshheading:8446254-... | lld:pubmed |
pubmed-article:8446254 | pubmed:year | 1993 | lld:pubmed |
pubmed-article:8446254 | pubmed:articleTitle | Antibiotics and energy delivery to the phagocytosis-associated respiratory burst in chronic hemodialysis patients: a comparison of cefodizime and cotrimoxazole. | lld:pubmed |
pubmed-article:8446254 | pubmed:affiliation | Nephrology Department, University Hospital, Ghent, Belgium. | lld:pubmed |
pubmed-article:8446254 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:8446254 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:8446254 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:8446254 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8446254 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8446254 | lld:pubmed |